Chemical formula: C₂₀H₂₂N₂S Molecular mass: 322.467 g/mol PubChem compound: 4066
Mequitazine interacts in the following cases:
The association of mequitazine with other central nervous system depressive drugs may major the central depression. Therefore, due to a possible reduced level of alertness, driving or operating machinery may be dangerous.
Caution should be exercised when co-administering mequitazine with sympathomimetic amines, as their adrenergic effect on the cardiovascular system is exacerbated.
Enhancement of the sedative effects of H1 antihistamines with the use of alcohol may occur in individual patients. Avoid the consumption of alcoholic drinks and medicines containing alcohol.
In patients with severe liver impairment there is a risk of reduced clearance and an accumulation of mequitazine.
An enhancement of atropine undesirable effects (e.g: urinary retention, constipation, dryness of the mouth) could be observed in association of mequitazine with atropine and related drugs.
As with all antihistamines, mequitazine should be used with caution in epilepsy. Epileptic patients should be closely monitored because of a possible lowering of the epileptogenic threshold, known to occur with phenothiazines.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
